The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.
May 29, 2025
Foley Viewpoints
Keep Wining: Franchise Statute Opens Door to Protections for Missouri Wine Distributor
The Eighth Circuit recently applied a novel, broad reading of the Missouri Franchise Act granting franchise protection to distributors…